Biotech Acquisition Company (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on September 3, 2020. The Company was formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company has one wholly owned subsidiary which was formed on November 8, 2021, Blade Merger Subsidiary, Inc., a Delaware corporation.
Company profile
Ticker
BIOT, BIOTU, BIOTW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Biotech Acquisition Company
SEC CIK
BIOT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Feb 23
25-NSE
Exchange delisting
2 Feb 23
8-K
Biotech Acquisition Company Announces Liquidation
1 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
25 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Jan 23
DEF 14A
Definitive proxy
4 Jan 23
8-K
Entry into a Material Definitive Agreement
22 Dec 22
PRE 14A
Preliminary proxy
21 Dec 22
10-Q
2022 Q3
Quarterly report
21 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
Latest ownership filings
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
14 Feb 23
SC 13G
GLAZER CAPITAL, LLC
14 Feb 23
SC 13G/A
Beryl Capital Management LLC
13 Feb 23
SC 13G/A
ARISTEIA CAPITAL LLC
13 Feb 23
SC 13G
Radcliffe Capital Management, L.P.
27 Jan 23
SC 13G
Hudson Bay Capital Management LP
25 Jan 23
SC 13G
Beryl Capital Management LLC
16 May 22
SC 13G
Biotech Sponsor LLC
14 Feb 22
SC 13G/A
Atalaya Capital Management LP
14 Feb 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.15 k | 13.15 k | 13.15 k | 13.15 k | 13.15 k | |
Cash burn (monthly) | (no burn) | 32.44 k | 82.19 k | 311.52 k | 8.53 k | |
Cash used (since last report) | n/a | 612.36 k | 1.55 mm | 5.88 mm | 160.98 k | |
Cash remaining | n/a | -599.21 k | -1.54 mm | -5.87 mm | -147.84 k | |
Runway (months of cash) | n/a | -18.5 | -18.7 | -18.8 | -17.3 |
Institutional ownership, Q3 2023
31.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.45 mm |
Total shares | 7.25 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotech Sponsor | 5.75 mm | $0.00 |
Vellar Opportunities Fund Master | 1.50 mm | $15.45 mm |
Proequities | 0.00 | $0.00 |